{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:26:10Z","timestamp":1789565170944,"version":"build-2803163510"},"reference-count":41,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Objective\u2003Most von Willebrand disease (VWD) patients can be treated with desmopressin during bleeding or surgery. Large interpatient variability is observed in von Willebrand factor (VWF) activity levels after desmopressin administration. The aim of this study was to develop a pharmacokinetic (PK) model to describe, quantify, and explain this variability.<\/jats:p><jats:p>Methods\u2003Patients with either VWD or low VWF, receiving an intravenous desmopressin test dose of 0.3 \u00b5g kg\u22121, were included. A PK model was derived on the basis of the individual time profiles of VWF activity. Since no VWF was administered, the VWF dose was arbitrarily set to unity. Interpatient variability in bioavailability (F), volume of distribution (V), and clearance (Cl) was estimated.<\/jats:p><jats:p>Results\u2003The PK model was developed using 951 VWF activity level measurements from 207 patients diagnosed with a VWD type. Median age was 28 years (range: 5\u201376), median predose VWF activity was 0.37\u2009IU\/mL (range: 0.06\u20131.13), and median VWF activity response at peak level was 0.64\u2009IU\/mL (range: 0.04\u20134.04). The observed PK profiles were best described using a one-compartment model with allometric scaling. While F increased with age, Cl was dependent on VWD type and sex. Inclusion resulted in a drop in interpatient variability in F and Cl of 81.7 to 60.5% and 92.8 to 76.5%, respectively.<\/jats:p><jats:p>Conclusion\u2003A PK model was developed, describing VWF activity versus time profile after desmopressin administration in patients with VWD or low VWF. Interpatient variability in response was quantified and partially explained. This model is a starting point toward more accurate prediction of desmopressin dosing effects in VWD.<\/jats:p>","DOI":"10.1055\/s-0040-1714349","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T23:02:43Z","timestamp":1596495763000},"page":"1407-1416","source":"Crossref","is-referenced-by-count":5,"title":["Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration"],"prefix":"10.1055","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-1633","authenticated-orcid":false,"given":"Nico C. B.","family":"de Jager","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy-Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Heijdra","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology, Erasmus University Medical Centre - Sophia Children's Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quincy","family":"Kieboom","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology, Erasmus University Medical Centre - Sophia Children's Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J. H. A.","family":"Kruip","sequence":"additional","affiliation":[{"name":"Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W. G.","family":"Leebeek","sequence":"additional","affiliation":[{"name":"Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjon H.","family":"Cnossen","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology, Erasmus University Medical Centre - Sophia Children's Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A. A.","family":"Math\u00f4t","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy-Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the OPTI-CLOT Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"issue":"21","key":"ref1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand's disease","volume":"375","author":"F WG Leebeek","year":"2016","journal-title":"N Engl J Med"},{"issue":"20","key":"ref2","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2015-11-664680","article-title":"Rapid discrimination of the phenotypic variants of von Willebrand disease","volume":"127","author":"J C Roberts","year":"2016","journal-title":"Blood"},{"issue":"10","key":"ref3","first-page":"2113","article-title":"von Willebrand factor and von Willebrand disease","volume":"57","author":"T Matsui","year":"2016","journal-title":"Rinsho Ketsueki"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"J E Sadler","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref5","first-page":"338","article-title":"Monitoring therapy during treatment of von Willebrand disease","volume":"43","author":"E J Favaloro","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"17","key":"ref6","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease","volume":"126","author":"J C Gill","year":"2015","journal-title":"Blood"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology","volume":"167","author":"M A Laffan","year":"2014","journal-title":"Br J Haematol"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/hae.12732","article-title":"Side effects of desmopressin in patients with bleeding disorders","volume":"22","author":"S CM Stoof","year":"2016","journal-title":"Haemophilia"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"W L Nichols","year":"2008","journal-title":"Haemophilia"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(77)91197-7","article-title":"1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases","volume":"1","author":"P M Mannucci","year":"1977","journal-title":"Lancet"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1055\/s-0038-1646050","article-title":"Intranasal and intravenous administration of desmopressin: effect on F VIII\/vWF, pharmacokinetics and reproducibility","volume":"58","author":"S Lethagen","year":"1987","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.7326\/0003-4819-103-1-6","article-title":"Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin","volume":"103","author":"B de la Fuente","year":"1985","journal-title":"Ann Intern Med"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1055\/s-0038-1646051","article-title":"Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses","volume":"58","author":"P M Mannucci","year":"1987","journal-title":"Thromb Haemost"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(77)91197-7","article-title":"1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases","volume":"1","author":"P M Mannucci","year":"1977","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/B978-0-323-05876-6.00080-0","article-title":"Other blood and immune disorders in chronic kidney disease","volume":"84","author":"W H\u00f6rl","year":"2010","journal-title":"Comprhensive Clinical Nephrology"},{"issue":"S 01","key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2007.01609.x","article-title":"Desmopressin: an historical introduction","volume":"14","author":"P M Mannucci","year":"2008","journal-title":"Haemophilia"},{"issue":"14","key":"ref17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s40265-017-0793-2","article-title":"Current and emerging options for the management of inherited von Willebrand disease","volume":"77","author":"J M Heijdra","year":"2017","journal-title":"Drugs"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2003-06-2072","article-title":"Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study","volume":"103","author":"A B Federici","year":"2004","journal-title":"Blood"},{"issue":"07","key":"ref20","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/jth.12964","article-title":"Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH","volume":"13","author":"I Bod\u00f3","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1160\/TH12-04-0244","article-title":"Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease","volume":"108","author":"E M de Wee","year":"2012","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjh.15277","article-title":"Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease","volume":"182","author":"F Atiq","year":"2018","journal-title":"Br J Haematol"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"L Lindbom","year":"2005","journal-title":"Comput Methods Programs Biomed"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","article-title":"Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM","volume":"101","author":"R J Keizer","year":"2011","journal-title":"Comput Methods Programs Biomed"},{"issue":"02","key":"ref25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming","volume":"75","author":"L Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1111\/jth.14292","article-title":"Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery","volume":"16","author":"T Preijers","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jth.12586","article-title":"von Willebrand disease and aging: an evolving phenotype","volume":"12","author":"Y V Sanders","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0008-6363(97)00039-4","article-title":"von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?","volume":"34","author":"G YH Lip","year":"1997","journal-title":"Cardiovasc Res"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1152\/jappl.2001.91.4.1893","article-title":"Sex differences in osmotic regulation of AVP and renal sodium handling","volume":"91","author":"N S Stachenfeld","year":"2001","journal-title":"J Appl Physiol (1985)"},{"issue":"01","key":"ref30","first-page":"41","article-title":"Perils, problems, and progress in laboratory diagnosis of von Willebrand disease","volume":"40","author":"V H Flood","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00228-017-2386-0","article-title":"Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis","volume":"74","author":"R Michelet","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2147\/CIA.S136931","article-title":"Von Willebrand disease in the elderly: clinical perspectives","volume":"13","author":"J Chapin","year":"2018","journal-title":"Clin Interv Aging"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/hae.12664","article-title":"Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease","volume":"21","author":"N Rydz","year":"2015","journal-title":"Haemophilia"},{"issue":"05","key":"ref34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1055\/s-0031-1281037","article-title":"Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients","volume":"37","author":"A B Federici","year":"2011","journal-title":"Semin Thromb Hemost"},{"issue":"13","key":"ref35","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood-2014-08-528398","article-title":"Diagnostic approach to von Willebrand disease","volume":"125","author":"C Ng","year":"2015","journal-title":"Blood"},{"issue":"08","key":"ref36","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2018-10-844936","article-title":"How I treat low von Willebrand factor levels","volume":"133","author":"M Lavin","year":"2019","journal-title":"Blood"},{"issue":"05","key":"ref37","doi-asserted-by":"crossref","first-page":"F1116","DOI":"10.1152\/ajprenal.00741.2010","article-title":"Gender difference in antidiuretic response to desmopressin","volume":"300","author":"K V Juul","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"issue":"02","key":"ref38","doi-asserted-by":"crossref","first-page":"F433","DOI":"10.1152\/ajprenal.00199.2010","article-title":"Sex differences in vasopressin V2 receptor expression and vasopressin-induced antidiuresis","volume":"300","author":"J Liu","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"issue":"01","key":"ref39","first-page":"1159","article-title":"Gonadal hormone regulation of the renal vasopressin V2 receptor","volume":"22","author":"J Liu","year":"2008","journal-title":"FASEB J"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/jth.12927","article-title":"CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease","volume":"13","author":"Y V Sanders","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/CIRCULATIONAHA.109.869156","article-title":"Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium","volume":"121","author":"N L Smith","year":"2010","journal-title":"Circulation"},{"issue":"26","key":"ref42","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1182\/blood-2012-10-457507","article-title":"The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels","volume":"121","author":"N Rydz","year":"2013","journal-title":"Blood"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1714349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T07:09:32Z","timestamp":1696489772000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1714349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,9,23]]},"published-print":{"date-parts":[[2020,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1714349","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]}}}